Using Rituximab to treat pulmonary arterial hypertension in lupus patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effects of Rituximab on disease progression in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH) who are receiving standard medical therapy. It is a prospective, single-arm, single-center study that will assess clinical responses and safety measures over time. Participants will receive two intravenous infusions of Rituximab, and the study will also investigate biomarkers related to treatment efficacy and autoantibody responses. The trial aims to provide insights into the safety and effectiveness of Rituximab in this specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1. Subject has provided written informed consent.
* 2. Subject must be between the ages of 18 and 65, inclusive at the time of recruitment
* 3. Clinical diagnosis of systemic lupus erythematosus. Diagnosis of SLE-PAH within the past 5 years, with a mean pulmonary arterial pressure (mPAP) of ≥ 25 mmHg, PAWP ≤15mmHg, mean PVR of \> 3 Wood units at entry.
* 4. WHO Functional Class II, III, or IV.
* 5. Subjects must have been treated with background medical therapy for PAH (prostanoid, endothelin receptor antagonist, PDE-5 inhibitor, and/or guanylate cyclase stimulators) for a minimum of 8 weeks and have been on stable dose(s) of those medical therapy(ies) for at least 4 weeks prior to randomization with no expectation of change for 24 weeks after randomization.

Exclusion Criteria:

* 1. Treatment with immunocompromising biologic agents (including, but not limited to TNF inhibitors, anakinra, abatacept, and tocilizumab) within 4 weeks prior to treatment initiation or treatment with infliximab within 8 weeks prior to treatment initiation.
* 2. SLE combined with important organ damage endangers life:

  1. Neuropsychiatric lupus with high risk such as status epilepticus;
  2. Refractory thrombocytopenic purpura has a clear bleeding tendency;
  3. Pulmonary alveolar hemorrhage leads to respiratory failure;
* 3. Uncontrolled infection;
* 4. Severe organ dysfunction:

  1. Patients with moderate or severe liver function impairment (Child-Pugh grade B and C);
  2. Patients with left ventricular dysfunction (left ventricular ejection fraction\<45%);
* 5. Other diseases are limited to completing a 6-minute walking test: angina pectoris, vascular, musculoskeletal lesions, etc
* 6. Abnormal laboratory test: platelet\<100 × 109/L, or hemoglobin\<9 g/dL, or white blood cell count\<3 × 109/L, or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) greater than 1.5 times the upper limit of normal value, or total bilirubin and blood lipids greater than 2 times the upper limit of normal value
* 7. Persistent hypotension, i.e. systolic blood pressure (SBP)\<90 mmHg
* 8. PAH caused by any reason other than SLE: other rheumatic diseases (such as SSc, rheumatoid arthritis, dermatomyositis, etc.); Portal hypertension, hereditary hemorrhagic telangiectasia, etc; Congenital heart disease; Suspicious drugs and poisons;
* 9. Chronic hypoxic disease related pulmonary hypertension: moderate or severe obstructive pulmonary disease: FEV1\<55%; Moderate or severe restrictive pulmonary disease: TLC\<60%;
* 10. Chronic thromboembolic pulmonary hypertension: Pulmonary ventilation/perfusion imaging indicates moderate to high suspicion of pulmonary thromboembolism;
* 11. Existing infections or uncontrollable infections that require antibiotic or antiviral treatment;
* 12. Women who are breastfeeding or pregnant or who plan to become pregnant during the study;
* 13. History of malignant tumors in the past 5 years
* 14. Mental, addictive, or other illnesses that restrict patients from providing informed consent or complying with research requirements;
* 15. Any condition or treatment that the investigator believes puts the subject at an unacceptable risk as a test participant.

Where it's running

• Peking Union Medical College Hospital
  Beijing, Beijing, China Recruiting

Study contacts

• Principal investigator: Mengtao Li, Prof — Peking Union Medical College Hospital
• Study coordinator: Mengtao Li, Prof
• Email: mengtao.li@cstar.org.cn
• Phone: 86-10-69159958

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of anifrolumab on arterial inflammation in SLE patients

  This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.

  Recruiting University of Cambridge · Cambridge, Cambridgeshire · NCT07913919

• Home urine testing for people with lupus

  Participants with lupus will try weekly home urine tests in addition to usual care to see if this helps monitor kidney health over a year.

  Recruiting NYU Langone Health · New York, New York · NCT07823478

• Understanding how low-load leg exercises affect muscle and blood flow in PAH patients

  This substudy tests whether a gentle leg exercise program can change blood flow and oxygen use in the calf muscles of adults with pulmonary arterial hypertension.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07781709

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

• Biomarker tests in adults with lupus to see how kidney disease changes over time

  Researchers will follow adults with lupus to see if blood and urine biomarkers can predict kidney involvement, flares, and treatment responses during routine care.

  Recruiting Oslo University Hospital · Oslo, Oslo · NCT07666711

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.